1.76 USD
▲+0.01+0.57%
盘后 2.07 0.00%
2026-09-16
市值
$12.97M
市盈率
—
EPS
-3.05
股息率
—
52 周区间
0.82 – 3.79
成交量
375.44K
Beta
0.74
目标价
5.26
52W 低 0.8252W 高 3.79
价格走势
公司简介
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to mo...